European Commission has approved Braftovi in combination with Mektovi for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. This approval is applicable to all 28 European Union member states, as well as Liechtenstein, Iceland and Norway.
European Commission approves Braftovi + Mektovi for advanced BRAF-mutant melanoma
YOU MAY BE INTERESTED IN
The National Coalition for Cancer Survivorship has provided the Cancer History Project with a rich archive of its newsletters: the NCCS Networker, volumes 1-11.